Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hovione’s Portugal Site Passes Inspection | Contract Pharma

What are you searching for?

Sign in
Breaking News

Hovione’s Portugal Site Passes Inspection

Successfully passes 12 inspections in 18 months

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hovione has successfully passed a GMP and Postmarket Approval inspection by the FDA at its plant in Loures, Portugal. The inspection lasted five days and concluded September 27th with no Form 483 issued. The inspector was satisfied with Hovione’s GMP System, inspection organization, and its team members.
 
“We are pleased to have another successful FDA inspection at our Loures plant completed,” said Guy Villax, Hovione’s chief executive officer. “Doing well in the eyes of an FDA inspector is always a motive of satisfaction and a good reason to congratulate one’s team. With 65 client audits and inspections per year our sites are always inspection-ready.”
 
Hovione’s five plants have successfully passed 12 inspections in the past 18 months by the US FDA in Portugal, Ireland, Macau and NJ; three by the Portuguese Health Authority (INFARMED) in Portugal, Macau and China, which led to GMP certificates; one by the Irish Medicines Board (IMB) at its Cork plant, which resulted in GMP certificates; one by the Korean FDA in the Portuguese plant; and two by the CFDA in China.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics